{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:10:32Z","timestamp":1781129432952,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"DOI":"10.7759\/cureus.103843","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:01:02Z","timestamp":1771434062000},"source":"Crossref","is-referenced-by-count":1,"title":["Advances in the Diagnosis and Disease-Modifying Management of Transthyretin Amyloid Cardiomyopathy: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Vasudeva","family":"Vijaykumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134785","article-title":"Transthyretin amyloid cardiomyopathy-2025 update: current diagnostic approaches and emerging therapeutic options","volume":"14","author":"Tsch\u00f6pe C","year":"2025","unstructured":"Tsch\u00f6pe C, Elsanhoury A, Kristen AV. Transthyretin amyloid cardiomyopathy-2025 update: current diagnostic approaches and emerging therapeutic options. J Clin Med. 2025, 14:4785. 10.3390\/jcm14134785","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf667","article-title":"Transthyretin amyloid cardiomyopathy: from cause to novel treatments","volume":"47","author":"Fontana M","year":"2026","unstructured":"Fontana M, Aimo A, Emdin M, Porcari A, Solomon SD, Hawkins PN, Gillmore JD. Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Eur Heart J. 2026, 47:54-63. 10.1093\/eurheartj\/ehaf667","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176089","article-title":"Transthyretin amyloid cardiomyopathy treatment: an updated review","volume":"14","author":"Wanniarachchige D","year":"2025","unstructured":"Wanniarachchige D, Khan S, Pan S. Transthyretin amyloid cardiomyopathy treatment: an updated review. J Clin Med. 2025, 14:6089. 10.3390\/jcm14176089","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.863179","article-title":"Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond","volume":"9","author":"Irabor B","year":"2022","unstructured":"Irabor B, McMillan JM, Fine NM. Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond. Front Cardiovasc Med. 2022, 9:863179. 10.3389\/fcvm.2022.863179","journal-title":"Front Cardiovasc Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles RM","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, et al.. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019, 7:709-16. 10.1016\/j.jchf.2019.04.010","journal-title":"JACC Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari A","year":"2024","unstructured":"Porcari A, Sinagra G, Gillmore JD, Fontana M, Hawkins PN. Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy. Eur J Intern Med. 2024, 123:29-36. 10.1016\/j.ejim.2024.01.001","journal-title":"Eur J Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10552-9","article-title":"Transthyretin cardiac amyloidosis: advances and ambiguities","volume":"30","author":"Danilov A","year":"2025","unstructured":"Danilov A, D'Angelo L, Marsela E, Costabel JP, Jorde UP, Rochlani Y. Transthyretin cardiac amyloidosis: advances and ambiguities. Heart Fail Rev. 2025, 30:1341-52. 10.1007\/s10741-025-10552-9","journal-title":"Heart Fail Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2026.103263","article-title":"Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review","volume":"51","author":"Zhu Y","year":"2026","unstructured":"Zhu Y, Gao S, Liu Q, Shen C. Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review. Curr Probl Cardiol. 2026, 51:103263. 10.1016\/j.cpcardiol.2026.103263","journal-title":"Curr Probl Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week","volume":"75","author":"Hanna M","year":"2020","unstructured":"Hanna M, Ruberg FL, Maurer MS, et al.. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020, 75:2851-62. 10.1016\/j.jacc.2020.04.022","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2025.102448","article-title":"How to perform and interpret cardiac amyloidosis radionuclide imaging (CARI)","volume":"51","author":"Benz DC","year":"2025","unstructured":"Benz DC, Flammer AJ, Schwotzer R, Buechel RR. How to perform and interpret cardiac amyloidosis radionuclide imaging (CARI). J Nucl Cardiol. 2025, 51:102448. 10.1016\/j.nuclcard.2025.102448","journal-title":"J Nucl Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238458","article-title":"Non-invasive diagnostic algorithm in transthyretin cardiac amyloidosis: is bone scintigraphy always enough?","volume":"14","author":"Marchionni G","year":"2025","unstructured":"Marchionni G, Pecci G, Alfarano M, et al.. Non-invasive diagnostic algorithm in transthyretin cardiac amyloidosis: is bone scintigraphy always enough?. J Clin Med. 2025, 14:8458. 10.3390\/jcm14238458","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27020820","article-title":"Multimodal diagnosis of cardiac amyloidosis: integrating imaging, histochemistry, and proteomics of precise typing","volume":"27","author":"Kancerek J","year":"2026","unstructured":"Kancerek J, Zniszczo\u0142 \u0141, Lewandowski P, Wojnicz R. Multimodal diagnosis of cardiac amyloidosis: integrating imaging, histochemistry, and proteomics of precise typing. Int J Mol Sci. 2026, 27:820. 10.3390\/ijms27020820","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.4147","article-title":"Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"9","author":"Shah SJ","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, et al.. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. JAMA Cardiol. 2024, 9:25-34. 10.1001\/jamacardio.2023.4147","journal-title":"JAMA Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-25-0092","article-title":"Real-world clinical evidence with tafamidis in patients with transthyretin amyloid cardiomyopathy\u3000- a contemporary review","volume":"7","author":"Izumiya Y","year":"2025","unstructured":"Izumiya Y, Kuyama N, Hanatani S, Matsuzawa Y, Usuku H, Yamamoto E, Tsujita K. Real-world clinical evidence with tafamidis in patients with transthyretin amyloid cardiomyopathy\u3000- a contemporary review. Circ Rep. 2025, 7:599-603. 10.1253\/circrep.CR-25-0092","journal-title":"Circ Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","volume":"151","author":"Judge DP","year":"2025","unstructured":"Judge DP, Gillmore JD, Alexander KM, et al.. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial. Circulation. 2025, 151:601-11. 10.1161\/CIRCULATIONAHA.124.072771","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial","volume":"31","author":"Jering KS","year":"2025","unstructured":"Jering KS, Fontana M, Lairez O, et al.. Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial. Nat Med. 2025, 31:3560-8. 10.1038\/s41591-025-03851-z","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/phar.4639","article-title":"Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications","volume":"45","author":"Hellenbart EL","year":"2025","unstructured":"Hellenbart EL, Ipema HJ, Rodriguez-Ziccardi MC, Krishna H, DiDomenico RJ. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications. Pharmacotherapy. 2025, 45:124-44. 10.1002\/phar.4639","journal-title":"Pharmacotherapy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103481","article-title":"Pharmacological management of transthyretin amyloid cardiomyopathy: where we are and where we are going","volume":"14","author":"De Michieli L","year":"2025","unstructured":"De Michieli L, Lupi A, Sinigiani G, et al.. Pharmacological management of transthyretin amyloid cardiomyopathy: where we are and where we are going. J Clin Med. 2025, 14:3481. 10.3390\/jcm14103481","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15100472","article-title":"Cardiac amyloidosis: tribulations and new frontiers","volume":"15","author":"Nguyen DM","year":"2025","unstructured":"Nguyen DM, Ramazani N, Sodhi G, Tak T. Cardiac amyloidosis: tribulations and new frontiers. J Pers Med. 2025, 15:472. 10.3390\/jpm15100472","journal-title":"J Pers Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.31083\/RCM46181","article-title":"Transthyretin cardiac amyloidosis and heart failure: state-of-the-art review and practice guidance","volume":"26","author":"Bukhari S","year":"2025","unstructured":"Bukhari S, Hamza M, Malik A. Transthyretin cardiac amyloidosis and heart failure: state-of-the-art review and practice guidance. Rev Cardiovasc Med. 2025, 26:46181. 10.31083\/RCM46181","journal-title":"Rev Cardiovasc Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou A","year":"2023","unstructured":"Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023, 37:127-42. 10.1007\/s40259-023-00577-7","journal-title":"BioDrugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard AA","year":"2025","unstructured":"Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Fail Rev. 2025, 30:69-73. 10.1007\/s10741-024-10444-4","journal-title":"Heart Fail Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.70011","article-title":"Real-world effectiveness of targeted therapies in ATTR cardiomyopathy: a meta-analysis integrating population-based data","volume":"12","author":"Antonopoulos AS","year":"2025","unstructured":"Antonopoulos AS, Tsampras T, Terentes-Printzios D, Lazaros G, Tsioufis K, Vlachopoulos C. Real-world effectiveness of targeted therapies in ATTR cardiomyopathy: a meta-analysis integrating population-based data. ESC Heart Fail. 2025, 12:4475-85. 10.1002\/ehf2.70011","journal-title":"ESC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466778-advances-in-the-diagnosis-and-disease-modifying-management-of-transthyretin-amyloid-cardiomyopathy-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:01:03Z","timestamp":1771434063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466778-advances-in-the-diagnosis-and-disease-modifying-management-of-transthyretin-amyloid-cardiomyopathy-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.103843","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}